Drug intelligence / Profile preview

BSL_EP044 + lactobacillus BSL_PS6

Development stage
Preclinical
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

BSL_EP044 + lactobacillus BSL_PS6 is a **combination probiotic formulation**, likely classified as a medical food or dietary supplement, designed for the nutritional management of metabolic disturbances such as type 2 diabetes. The formulation contains specifically identified probiotic strains intended to support gut microbiome function. The combination acts primarily by restoring the body's production of butyrate and the gut mucin layer. Butyrate stimulates GLP-1 secretion in the gut, which can enhance satiety, reduce appetite, improve insulin secretion, reduce hepatic glucose output, and regulate gastric emptying. This may result in lower postprandial glucose levels and support glycemic control. Clinical evidence suggests a role for probiotic blends in reducing glucose area under the curve and possibly decreasing A1C in adults with type 2 diabetes, particularly as add-on therapy. The formulation is usually taken orally, typically twice daily with food, and is refrigerated after opening. The specific strain BSL_PS6 appears to be a Lactobacillus with properties consistent with immunomodulation, competition with pathogenic organisms, and gut barrier support[1][2][4][6].

02

Targets

Shigella spp. (Shigella species)

Beyond the preview

Go deeper on BSL_EP044 + lactobacillus BSL_PS6.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BSL_EP044 + lactobacillus BSL_PS6.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call